Found: 17
Select item for more details and to access through your institution.
How to balance valuable innovation with affordable access to medicines in Belgium?
- Published in:
- Frontiers in Pharmacology, 2022, v. 13, p. 1, doi. 10.3389/fphar.2022.960701
- By:
- Publication type:
- Article
Biosimilar Use and Switching in Belgium: Avenues for Integrated Policymaking.
- Published in:
- Frontiers in Pharmacology, 2022, v. 13, p. 1, doi. 10.3389/fphar.2022.821616
- By:
- Publication type:
- Article
Off-Patent Biologicals and Biosimilars Tendering in Europe—A Proposal towards More Sustainable Practices.
- Published in:
- Pharmaceuticals (14248247), 2021, v. 14, n. 6, p. 499, doi. 10.3390/ph14060499
- By:
- Publication type:
- Article
Informing a European guidance framework on electronic informed consent in clinical research: a qualitative study.
- Published in:
- BMC Health Services Research, 2023, v. 23, n. 1, p. 1, doi. 10.1186/s12913-023-09173-5
- By:
- Publication type:
- Article
Personalized and longitudinal electronic informed consent in clinical trials: How to move the needle?
- Published in:
- Digital Health, 2024, p. 1, doi. 10.1177/20552076231222361
- By:
- Publication type:
- Article
Perceptions About Biosimilar Medicines Among Belgian Patients in the Ambulatory Care.
- Published in:
- Frontiers in Pharmacology, 2022, v. 12, p. 1, doi. 10.3389/fphar.2021.789640
- By:
- Publication type:
- Article
Correction to: Interchangeability of Biosimilars: Overcoming the Final Hurdles.
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
Interchangeability of Biosimilars: Overcoming the Final Hurdles.
- Published in:
- Drugs, 2021, v. 81, n. 16, p. 1897, doi. 10.1007/s40265-021-01629-4
- By:
- Publication type:
- Article
Opportunities and Challenges in Cross-Country Collaboration: Insights from the Beneluxa Initiative.
- Published in:
- Journal of Market Access & Health Policy, 2024, v. 12, n. 3, p. 144, doi. 10.3390/jmahp12030012
- By:
- Publication type:
- Article
Uncertainty management in regulatory and health technology assessment decision-making on drugs: guidance of the HTAi-DIA Working Group.
- Published in:
- International Journal of Technology Assessment in Health Care, 2023, v. 39, n. 1, p. 1, doi. 10.1017/S0266462323000375
- By:
- Publication type:
- Article
How to select a best-value biological medicine? A practical model to support hospital pharmacists.
- Published in:
- American Journal of Health-System Pharmacy, 2022, v. 79, n. 22, p. 2001, doi. 10.1093/ajhp/zxac235
- By:
- Publication type:
- Article
The arrival of biosimilar monoclonal antibodies in oncology: clinical studies for trastuzumab biosimilars.
- Published in:
- 2019
- By:
- Publication type:
- journal article
The Efficacy, Safety, and Immunogenicity of Switching Between Reference Biopharmaceuticals and Biosimilars: A Systematic Review.
- Published in:
- Clinical Pharmacology & Therapeutics, 2020, v. 108, n. 4, p. 734, doi. 10.1002/cpt.1836
- By:
- Publication type:
- Article
Heart failure patients' perspectives on treatment outcomes and unmet medical needs: A qualitative preference study.
- Published in:
- ESC Heart Failure, 2024, v. 11, n. 5, p. 3075, doi. 10.1002/ehf2.14891
- By:
- Publication type:
- Article
How can patient preferences be used and communicated in the regulatory evaluation of medicinal products? Findings and recommendations from IMI PREFER and call to action.
- Published in:
- Frontiers in Pharmacology, 2023, p. 1, doi. 10.3389/fphar.2023.1192770
- By:
- Publication type:
- Article
European Stakeholder Learnings Regarding Biosimilars: Part I—Improving Biosimilar Understanding and Adoption.
- Published in:
- BioDrugs, 2020, v. 34, n. 6, p. 783, doi. 10.1007/s40259-020-00452-9
- By:
- Publication type:
- Article
European Stakeholder Learnings Regarding Biosimilars: Part II—Improving Biosimilar Use in Clinical Practice.
- Published in:
- BioDrugs, 2020, v. 34, n. 6, p. 797, doi. 10.1007/s40259-020-00440-z
- By:
- Publication type:
- Article